Real‐world data on the efficacy and safety of immune‐checkpoint inhibitors in elderly patients with non‐small cell lung cancer

Real‐world data on the efficacy and safety of immune‐checkpoint inhibitors in elderly patients with non‐small cell lung cancer

Abstract Purpose Immune‐checkpoint inhibitors (ICIs) are effective against advanced non‐small cell lung cancer (NSCLC). However, whether the efficacy and safety of ICI treatment in elderly patients are similar to those in younger patients is unclear. This study was designed to address this question....

Full description

Bibliographic Details
Main Authors: Daisuke Morinaga, Hajime Asahina, Shotaro Ito, Osamu Honjo, Hisashi Tanaka, Ryoichi Honda, Hiroshi Yokouchi, Keiichi Nakamura, Kei Takamura, Fumihiro Hommura, Yasutaka Kawai, Kenichiro Ito, Noriaki Sukoh, Keiki Yokoo, Ryo Morita, Toshiyuki Harada, Taichi Takashina, Tomohiro Goda, Hirotoshi Dosaka‐Akita, Hiroshi Isobe, the Hokkaido Lung Cancer Clinical Study Group Trial
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:Cancer Medicine
Subjects:
elderly patient
immune‐checkpoint inhibitor
non‐small cell lung cancer
Online Access:https://doi.org/10.1002/cam4.5889

Internet

https://doi.org/10.1002/cam4.5889

Similar Items